Leukemia

Toxicity in this phase 3 trial was comparable with prior reports of chemotherapy among patients with relapsed/refractory acute myeloid leukemia.

The benefit-risk profile of asciminib may change the chronic myeloid leukemia treatment paradigm, according to Jorge E. Cortes, MD.

A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.

Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.

Phase 3b data support venetoclax as a treatment option in CLL for patients with or without B-cell receptor–associated kinase inhibitor treatment.

Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.

Preliminary findings from the MB-106 trial support the potential benefit of annamycin/cytarabine in patients with acute myeloid leukemia.

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Findings from SELECT-AML-1 support the potential benefit of tamibarotene in those with acute myeloid leukemia harboring RARA gene overexpression.

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.

Data from the phase 2 AUGMENT-101 trial support the biologics license application for revumenib in patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Study authors note that access to multidisciplinary teams and transportation programs may help mitigate hematopoietic cell transplantation outcome disparities.

Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Data from the phase 3 VIALE-A trial showed continued responses during long-term follow-up for patients with newly diagnosed acute myeloid leukemia treated with venetoclax/azacitidine.

The phase 3 ALPINE and ASCEND studies were used in the MAIC analysis assessing zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Findings from an open-label trial support the FDA approval of inotuzumab ozogamicin as a treatment for pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Investigators are evaluating IO-202 in patients with newly diagnosed chronic myelomonocytic leukemia as part of a phase 1 dose expansion trial.

A phase 1/2 study found that using azacitidine, venetoclax, and gilteritinib for patients with FLT3-mutated acute myeloid leukemia yielded high rates of complete response and complete response with incomplete hematologic recovery.

Findings from the phase 1/2 TRANSCEND CLL 004 trial support lisocabtagene maraleucel as a potential new treatment option for relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Findings from a retrospective study demonstrate the feasibility of using brexucabtagene autoleucel to treat patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.

A panel of oncology experts discuss recent advancements surrounding novel therapies for CLL, exploring their potential impact on future treatment paradigms.

Measurable residual disease–guided ibrutinib plus venetoclax in chronic lymphocytic leukemia appears to be particularly beneficial in patients with unmutated IGHV and specific genetic abnormalities.

Rachel Rau, MD, gives her perspective on the use of asparaginase treatments for pediatric patients with acute lymphocytic leukemia.

Sameer A Parikh, MD, leads an expert discussion regarding emerging resistance data and its potential impact on treatment sequencing.

Sikander Ailawadhi, MD, review real-world data findings recently presented at ASH 2023, highlighting their potential implications on the treatment landscape.

Administering pegylated asparaginase continuously to pediatric patients with acute lymphoblastic leukemia appears to be safe without compromising the efficacy of treatment.

HEMO-CAR-T can now proceed with its evaluation as a treatment for those with acute myeloid leukemia as part of a phase 1 trial.

Vanderbilt University Medical Center and Winship Cancer Institute at Emory University Face Off on recent data in multiple myeloma and acute lymphoblastic leukemia.

Investigators discontinued the phase 3 ENHANCE-3 study after magrolimab plus azacitidine and venetoclax yielded an increased risk of death in those with acute myeloid leukemia.

The FDA sets a Prescription Drug User Fee Action date of June 21, 2024 for blinatumomab as a treatment for those with CD19-positive B-cell precursor acute lymphoblastic leukemia.